Abstract
The Heart Outcomes Prevention Evaluation Study investigators (Jan. 20 issue)1 found that the administration of ramipril to a population of high-risk patients significantly reduced the rates of myocardial infarction, stroke, and death from cardiovascular causes. However, the data provided in this study raise questions as to whether angiotensin-converting–enzyme (ACE) inhibitors offer substantive clinical benefits over current therapeutic standards.

This publication has 16 references indexed in Scilit: